Par Pharmaceutical Companies, Inc. (NYSE:PRX)

Successful activist investors Relational Investors believes that Par is undervalued at this level and has accumulated 8.71% of the company's stock.

Deej

Trading at only 7.6Xcash flow/share, and at P/B and P/E ratios lower than industry averages.

Magic formula, insider buying. Earnings depressed by one-time charge.

Debt/equity of zero, Price/earnings of 12.28, market cap of 1.12 billion, Return on Invested Capital (TTM) of 15.81, based in New Jersey, United States, focus on generic drugs.

Covestor Model Manager Alphamark Advisors sold PRX in his Small Cap Growth Covestor Model ( http://covestor.com/Alphamark-Advisors )

Like their cash to debt ratio

lak/estrev+5/1.4b/A/genericRx

Quality company with great growth!!

Drugs Pick

Par pharmaceutical co is a holding company in the business of developing, manufacturing and distributing branded and generic drugs in the U.S. Earnings increased each of the last 3 qtrs., beating estimates by wide margin. Par sports of d/e .Per share T/B $9.93 Cash $6.04, and short interest 3.52%.

Par Pharmaceutical Companies is a holding company in the business of developing, manufacturing and distributing generic and branded drugs in the U.S. Par sports a D/E of .15, cash per share $6.04. cash flow $2.18 and a short interest of 3.52%. Earnings surged each of the last three quarters and pulverized estimates.

With the swine flu pandemic I only see the majority of pharmaceutical companies doing good

With larger coverage, larger sales force, larger everything in general the B-12 nasal spray will meet Par's profit requirements nicely. Anyone who has to take pills every day will appreciate a one time per week nasal spray! The population is aging. B-12 is something all of us old hippies can get busy with!

obama health plan increases use of generics

Over the next 3 years, $48B of branded drugs will go off patent, which will lead to generic drugs growing to 70 percent of the U.S. drug market place - PRX is strongly positioned ot take advantage of this shift in the marketplace

Another pharma play, good price level

Two words will boost this company: baby boomers. That combined with a faling health care system that intentionally plunges people into poverty will make discount drugs the place to be.

Granted, the above is only a justification for why this niche INDUSTRY will be good in the long term. There are still legitimate concerns about the financials on this company. However, given its place in foreign markets and the risk factor for any pharma company (especially one undercutting the majors), this is a bet that I believe will pay off.

No growth for 2008. Street hates that.

wow - take a look at the stats on this company. right at the moment, it appears to be beating the market as far as stock appreciation goes, but this baffles me . they have a net loss on growth,net loss on profit margins,operating margins are slim to say the least,dwindling cash flow charts. if you look at the balance sheet, you'll find a shrinking net assets base.revenues have shrunken to the negative area.this is a train wreck company. perhaps only weeks from announcing bankruptcy. my bet is ,someone has to take notice soon and this one will lag the market.